Compare Stocks: ACRV, SRZN, EDIT, and BCYC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.95 +5.4%	$1.68	$1.27 ▼ $3.56	$79.18M	1.85	279,677 shs	753,296 shs
BCYC Bicycle Therapeutics	$3.90 -2.0%	$4.10	$3.74 ▼ $9.16	$277.85M	1.55	305,130 shs	468,018 shs
EDIT Editas Medicine	$2.82 +0.4%	$2.89	$1.66 ▼ $4.54	$431.56M	2.14	1.50 million shs	1.47 million shs
SRZN Surrozen	$23.96 +1.0%	$22.94	$10.11 ▼ $35.00	$278.18M	0.52	283,674 shs	212,866 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+5.41%	+12.72%	+1.56%	+10.17%	+48.85%
BCYC Bicycle Therapeutics	-2.01%	-6.47%	-7.58%	-12.36%	-46.94%
EDIT Editas Medicine	+0.36%	-2.08%	-7.24%	+7.63%	-8.44%
SRZN Surrozen	+0.97%	-6.48%	+9.96%	-14.88%	+138.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.95 +5.4%	$1.68	$1.27 ▼ $3.56	$79.18M	1.85	279,677 shs	753,296 shs
BCYC Bicycle Therapeutics	$3.90 -2.0%	$4.10	$3.74 ▼ $9.16	$277.85M	1.55	305,130 shs	468,018 shs
EDIT Editas Medicine	$2.82 +0.4%	$2.89	$1.66 ▼ $4.54	$431.56M	2.14	1.50 million shs	1.47 million shs
SRZN Surrozen	$23.96 +1.0%	$22.94	$10.11 ▼ $35.00	$278.18M	0.52	283,674 shs	212,866 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+5.41%	+12.72%	+1.56%	+10.17%	+48.85%
BCYC Bicycle Therapeutics	-2.01%	-6.47%	-7.58%	-12.36%	-46.94%
EDIT Editas Medicine	+0.36%	-2.08%	-7.24%	+7.63%	-8.44%
SRZN Surrozen	+0.97%	-6.48%	+9.96%	-14.88%	+138.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	592.31% Upside
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	255.31% Upside
EDIT Editas Medicine	2.50	Moderate Buy	$5.40	91.49% Upside
SRZN Surrozen	2.67	Moderate Buy	$42.00	75.29% Upside

Current Analyst Ratings Breakdown

Latest ACRV, SRZN, EDIT, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
7/30/2026	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SRZN Surrozen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$2.02 per share	N/A
BCYC Bicycle Therapeutics	$61.21M	4.45	N/A	N/A	$7.29 per share	0.53
EDIT Editas Medicine	$40.52M	10.69	N/A	N/A	$0.69 per share	4.09
SRZN Surrozen	$11.51M	24.17	N/A	N/A	($18.83) per share	-1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$2.00	N/A	N/A	N/A	N/A	-70.14%	-61.60%	N/A
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	N/A
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	N/A

Latest ACRV, SRZN, EDIT, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	8.98
BCYC Bicycle Therapeutics	N/A	12.08	12.08
EDIT Editas Medicine	N/A	3.19	3.19
SRZN Surrozen	N/A	12.14	11.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
BCYC Bicycle Therapeutics	86.15%
EDIT Editas Medicine	71.90%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
BCYC Bicycle Therapeutics	22.00%
EDIT Editas Medicine	3.10%
SRZN Surrozen	31.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	42.80 million	38.31 million	Not Optionable
BCYC Bicycle Therapeutics	240	69.81 million	54.45 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable

ACRV, SRZN, EDIT, and BCYC Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for Surrozen Q3 Earnings?

August 14 at 1:28 AM | americanbankingnews.com

What is HC Wainwright's Estimate for Surrozen Q3 Earnings?

August 12 at 6:11 AM | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Surrozen (NASDAQ:SRZN)

August 12 at 1:48 AM | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN)

August 10, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS

August 6, 2026 | marketbeat.com

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN

August 2, 2026 | marketbeat.com

Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages

July 30, 2026 | marketbeat.com

Surrozen, Inc. $SRZN Position Reduced by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Upgraded by Zacks Research to Hold Rating

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock

July 29, 2026 | insidertrades.com

Surrozen Inc

July 28, 2026 | edition.cnn.com

Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock

July 28, 2026 | marketbeat.com

Surrozen highlights Wnt retina pipeline, SZN-8141 IND timeline at HC Wainwright

July 22, 2026 | msn.com

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright

July 22, 2026 | marketbeat.com

Surrozen to Present at Upcoming Healthcare Investor Conference

July 15, 2026 | globenewswire.com

Surrozen (SRZN) Stock Forecast & Price Target

June 4, 2026 | investing.com

We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate

May 17, 2026 | finance.yahoo.com

Surrozen (SRZN) price target increased by 10.11% to 43.52

May 14, 2026 | msn.com

Surrozen Shareholders Support Board, Auditor and Pay Policies

May 14, 2026 | tipranks.com

Surrozen to Present at Upcoming Healthcare Investor Conference

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACRV, SRZN, EDIT, and BCYC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.95 +0.10 (+5.41%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.51%)

As of 08/14/2026 07:39 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Bicycle Therapeutics NASDAQ:BCYC

$3.90 -0.08 (-2.01%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.92 +0.02 (+0.49%)

As of 08/14/2026 07:34 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Editas Medicine NASDAQ:EDIT

$2.82 +0.01 (+0.36%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.82 +0.01 (+0.18%)

As of 08/14/2026 07:34 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Surrozen NASDAQ:SRZN

$23.96 +0.23 (+0.97%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$23.92 -0.05 (-0.19%)

As of 08/14/2026 04:10 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, SRZN, EDIT, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, SRZN, EDIT, and BCYC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, SRZN, EDIT, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACRV, SRZN, EDIT, and BCYC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Bicycle Therapeutics NASDAQ:BCYC

Editas Medicine NASDAQ:EDIT

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, SRZN, EDIT, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, SRZN, EDIT, and BCYC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, SRZN, EDIT, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACRV, SRZN, EDIT, and BCYC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Bicycle Therapeutics NASDAQ:BCYC

Editas Medicine NASDAQ:EDIT

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools